Saniona AB
STO:SANION

Watchlist Manager
Saniona AB Logo
Saniona AB
STO:SANION
Watchlist
Price: 8.12 SEK 0.62% Market Closed
Market Cap: 903.3m SEK
Have any thoughts about
Saniona AB?
Write Note

Saniona AB
Long-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Saniona AB
Long-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Saniona AB
STO:SANION
Long-Term Investments
kr640k
CAGR 3-Years
-67%
CAGR 5-Years
-32%
CAGR 10-Years
N/A
Genmab A/S
CSE:GMAB
Long-Term Investments
kr196m
CAGR 3-Years
-36%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Zealand Pharma A/S
CSE:ZEAL
Long-Term Investments
kr746.1m
CAGR 3-Years
178%
CAGR 5-Years
85%
CAGR 10-Years
N/A
Ascendis Pharma A/S
NASDAQ:ASND
Long-Term Investments
€16.2m
CAGR 3-Years
-48%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
B
Bavarian Nordic A/S
CSE:BAVA
Long-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bioporto A/S
CSE:BIOPOR
Long-Term Investments
kr1.3m
CAGR 3-Years
-7%
CAGR 5-Years
12%
CAGR 10-Years
8%
No Stocks Found

Saniona AB
Glance View

Market Cap
903.3m SEK
Industry
Biotechnology

Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

SANION Intrinsic Value
3.56 SEK
Overvaluation 56%
Intrinsic Value
Price

See Also

What is Saniona AB's Long-Term Investments?
Long-Term Investments
640k SEK

Based on the financial report for Jun 30, 2024, Saniona AB's Long-Term Investments amounts to 640k SEK.

What is Saniona AB's Long-Term Investments growth rate?
Long-Term Investments CAGR 5Y
-32%

Over the last year, the Long-Term Investments growth was -83%. The average annual Long-Term Investments growth rates for Saniona AB have been -67% over the past three years , -32% over the past five years .

Back to Top